The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SPWR, MP and CABA

2022-03-16

NYSE - New York Stock Exchange · Uranium · Vanadium · Rare Earth Elements · Titanium · Zirconium · United States

NEW YORK, NY / ACCESSWIRE / March 16, 2022 /The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

SunPower Corporation (NASDAQ:SPWR)

Investors Affected : August 3, 2021 - January 20, 2022

A class action has commenced on behalf of certain shareholders in SunPower Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) certain connectors used by SunPower suffered from cracking issues; (2) as a result, the Company was reasonably likely to incur costs to remediate the faulty connectors; (3) as a result of the foregoing, SunPower's financial results would be adversely impacted; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/sunpower-corporation-loss-submission-form/?id=24771&from=1

MP Materials Corp. f/k/a Fortress Value Acquisition Corp. (NYSE:MP)

Investors Affected : May 1, 2020 - February 2, 2022

A class action has commenced on behalf of certain shareholders in MP Materials Corp f/k/a Fortress Value Acquisition Corp. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Fortress Value Acquisition Corp. ("FVAC") had overstated its due diligence efforts and expertise with respect to identifying target companies to acquire; (ii) FVAC performed inadequate due diligence into Legacy MP Materials prior to the business combination, or else ignored significant red flags regarding, inter alia, Legacy MP Materials' management, compliance policies, and Mountain Pass's profitability; (iii) as a result, the Company's future business and financial prospects post-business combination were overstated; (iv) MP Materials engaged in an abusive transfer price manipulation scheme with a related party in the People's Republic of China to artificially inflate the Company's profits; (v) MP Materials' ore at the Mountain Pass Rare Earth Mine and Processing Facility was not economically viable to harvest for rare earth metals; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/mp-materials-corp-f-k-a-fortress-value-acquisition-corp-loss-submission-form/?id=24771&from=1

Cabaletta Bio, Inc. (NASDAQ:CABA)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive.

A class action has commenced on behalf of certain shareholders in Cabaletta Bio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/cabaletta-bio-inc-loss-submission-form/?id=24771&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: dg@securitiesclasslaw.com Phone: (212) 537-9430 Fax: (833) 862-7770

SOURCE : The Gross Law Firm

View source version on accesswire.com: https://www.accesswire.com/693331/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-SPWR-MP-and-CABA